world
Eli Lilly's Mounjaro Becomes World's Top-Selling Drug in First Quarter
Mounjaro generated $8.7 billion in sales during the first quarter, surpassing Merck's Keytruda which recorded $7.9 billion. Keytruda had held the position of the world's best-selling drug since the beginning of 2023. The shift reflects changing revenue rankings among leading pharmaceutical products.
MO
indiatoday.intoday.inAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Eli Lilly's Mounjaro recorded $8.7 billion in sales in the first quarter, making it the world's best-selling drug. Merck's Keytruda, a cancer treatment, generated $7.9 billion in the same period. Keytruda had ranked as the top-selling drug since the start of 2023 before being overtaken by Mounjaro.
The company reported the first-quarter figures that placed Mounjaro ahead of all other pharmaceutical products worldwide.
Mounjaro's first-quarter performance exceeded Keytruda's by $800 million. The change ends a multi-year period during which Keytruda maintained the No. 1 position among all drugs by revenue. The updated rankings come from sales data for the three months ended March 31. No additional details on year-over-year growth rates or regional breakdowns were included in the report.
Transparency
2 sources · across multiple outlets
CorroborationModerate · 2 sources
